Tissue | Expression Dynamics | Abbreviation |
Breast | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Breast/VEGFA_pca_on_diff_genes.png) | IDC: Invasive ductal carcinoma |
DCIS: Ductal carcinoma in situ |
Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers |
Cervix | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Cervix/VEGFA_pca_on_diff_genes.png) | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/VEGFA_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/VEGFA_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Endometrium | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Endometrium/VEGFA_pca_on_diff_genes.png) | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/VEGFA_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/VEGFA_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/VEGFA_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/VEGFA_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/VEGFA_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/VEGFA_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:0036294112 | Thyroid | PTC | cellular response to decreased oxygen levels | 74/5968 | 161/18723 | 1.23e-04 | 9.75e-04 | 74 |
GO:0010632111 | Thyroid | PTC | regulation of epithelial cell migration | 123/5968 | 292/18723 | 1.33e-04 | 1.05e-03 | 123 |
GO:0061028111 | Thyroid | PTC | establishment of endothelial barrier | 27/5968 | 46/18723 | 1.57e-04 | 1.21e-03 | 27 |
GO:00519608 | Thyroid | PTC | regulation of nervous system development | 177/5968 | 443/18723 | 1.72e-04 | 1.32e-03 | 177 |
GO:0048608111 | Thyroid | PTC | reproductive structure development | 170/5968 | 424/18723 | 1.86e-04 | 1.41e-03 | 170 |
GO:000195420 | Thyroid | PTC | positive regulation of cell-matrix adhesion | 32/5968 | 58/18723 | 2.01e-04 | 1.50e-03 | 32 |
GO:00305167 | Thyroid | PTC | regulation of axon extension | 47/5968 | 95/18723 | 2.60e-04 | 1.86e-03 | 47 |
GO:0043154112 | Thyroid | PTC | negative regulation of cysteine-type endopeptidase activity involved in apoptotic process | 40/5968 | 78/18723 | 2.83e-04 | 2.01e-03 | 40 |
GO:003032317 | Thyroid | PTC | respiratory tube development | 80/5968 | 181/18723 | 3.23e-04 | 2.23e-03 | 80 |
GO:2000117112 | Thyroid | PTC | negative regulation of cysteine-type endopeptidase activity | 43/5968 | 86/18723 | 3.49e-04 | 2.40e-03 | 43 |
GO:190188817 | Thyroid | PTC | regulation of cell junction assembly | 88/5968 | 204/18723 | 4.50e-04 | 2.97e-03 | 88 |
GO:0036003111 | Thyroid | PTC | positive regulation of transcription from RNA polymerase II promoter in response to stress | 16/5968 | 24/18723 | 4.87e-04 | 3.20e-03 | 16 |
GO:001059516 | Thyroid | PTC | positive regulation of endothelial cell migration | 61/5968 | 133/18723 | 4.95e-04 | 3.25e-03 | 61 |
GO:190152213 | Thyroid | PTC | positive regulation of transcription from RNA polymerase II promoter involved in cellular response to chemical stimulus | 15/5968 | 22/18723 | 5.11e-04 | 3.32e-03 | 15 |
GO:00613873 | Thyroid | PTC | regulation of extent of cell growth | 52/5968 | 110/18723 | 5.20e-04 | 3.37e-03 | 52 |
GO:0003158111 | Thyroid | PTC | endothelium development | 62/5968 | 136/18723 | 5.45e-04 | 3.48e-03 | 62 |
GO:004544619 | Thyroid | PTC | endothelial cell differentiation | 55/5968 | 118/18723 | 5.64e-04 | 3.59e-03 | 55 |
GO:003032419 | Thyroid | PTC | lung development | 77/5968 | 177/18723 | 7.33e-04 | 4.58e-03 | 77 |
GO:003210316 | Thyroid | PTC | positive regulation of response to external stimulus | 167/5968 | 427/18723 | 8.31e-04 | 5.13e-03 | 167 |
GO:007145619 | Thyroid | PTC | cellular response to hypoxia | 67/5968 | 151/18723 | 8.31e-04 | 5.13e-03 | 67 |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0520818 | Breast | Precancer | Chemical carcinogenesis - reactive oxygen species | 68/684 | 223/8465 | 3.61e-23 | 1.14e-21 | 8.73e-22 | 68 |
hsa0516718 | Breast | Precancer | Kaposi sarcoma-associated herpesvirus infection | 36/684 | 194/8465 | 1.68e-06 | 2.53e-05 | 1.94e-05 | 36 |
hsa0541818 | Breast | Precancer | Fluid shear stress and atherosclerosis | 28/684 | 139/8465 | 4.74e-06 | 6.00e-05 | 4.59e-05 | 28 |
hsa0406616 | Breast | Precancer | HIF-1 signaling pathway | 23/684 | 109/8465 | 1.51e-05 | 1.59e-04 | 1.22e-04 | 23 |
hsa0532312 | Breast | Precancer | Rheumatoid arthritis | 19/684 | 93/8465 | 1.30e-04 | 1.14e-03 | 8.73e-04 | 19 |
hsa0520514 | Breast | Precancer | Proteoglycans in cancer | 30/684 | 205/8465 | 1.00e-03 | 7.18e-03 | 5.50e-03 | 30 |
hsa0516316 | Breast | Precancer | Human cytomegalovirus infection | 32/684 | 225/8465 | 1.13e-03 | 7.57e-03 | 5.80e-03 | 32 |
hsa052196 | Breast | Precancer | Bladder cancer | 9/684 | 41/8465 | 4.65e-03 | 2.72e-02 | 2.08e-02 | 9 |
hsa0520819 | Breast | Precancer | Chemical carcinogenesis - reactive oxygen species | 68/684 | 223/8465 | 3.61e-23 | 1.14e-21 | 8.73e-22 | 68 |
hsa0516719 | Breast | Precancer | Kaposi sarcoma-associated herpesvirus infection | 36/684 | 194/8465 | 1.68e-06 | 2.53e-05 | 1.94e-05 | 36 |
hsa0541819 | Breast | Precancer | Fluid shear stress and atherosclerosis | 28/684 | 139/8465 | 4.74e-06 | 6.00e-05 | 4.59e-05 | 28 |
hsa0406617 | Breast | Precancer | HIF-1 signaling pathway | 23/684 | 109/8465 | 1.51e-05 | 1.59e-04 | 1.22e-04 | 23 |
hsa0532313 | Breast | Precancer | Rheumatoid arthritis | 19/684 | 93/8465 | 1.30e-04 | 1.14e-03 | 8.73e-04 | 19 |
hsa0520515 | Breast | Precancer | Proteoglycans in cancer | 30/684 | 205/8465 | 1.00e-03 | 7.18e-03 | 5.50e-03 | 30 |
hsa0516317 | Breast | Precancer | Human cytomegalovirus infection | 32/684 | 225/8465 | 1.13e-03 | 7.57e-03 | 5.80e-03 | 32 |
hsa0521913 | Breast | Precancer | Bladder cancer | 9/684 | 41/8465 | 4.65e-03 | 2.72e-02 | 2.08e-02 | 9 |
hsa0520824 | Breast | IDC | Chemical carcinogenesis - reactive oxygen species | 71/867 | 223/8465 | 2.55e-19 | 7.53e-18 | 5.63e-18 | 71 |
hsa0541824 | Breast | IDC | Fluid shear stress and atherosclerosis | 34/867 | 139/8465 | 9.41e-07 | 1.61e-05 | 1.20e-05 | 34 |
hsa0520523 | Breast | IDC | Proteoglycans in cancer | 42/867 | 205/8465 | 7.69e-06 | 9.99e-05 | 7.48e-05 | 42 |
hsa0516723 | Breast | IDC | Kaposi sarcoma-associated herpesvirus infection | 38/867 | 194/8465 | 5.87e-05 | 5.96e-04 | 4.46e-04 | 38 |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
7422 | VEGFA | CLINICALLY ACTIONABLE, GROWTH FACTOR, CELL SURFACE, DRUGGABLE GENOME | | ANTHRACYCLINE | | 15297400 |
7422 | VEGFA | CLINICALLY ACTIONABLE, GROWTH FACTOR, CELL SURFACE, DRUGGABLE GENOME | | Carbamide derivative 17 | | |
7422 | VEGFA | CLINICALLY ACTIONABLE, GROWTH FACTOR, CELL SURFACE, DRUGGABLE GENOME | inhibitor | SORAFENIB TOSYLATE | | |
7422 | VEGFA | CLINICALLY ACTIONABLE, GROWTH FACTOR, CELL SURFACE, DRUGGABLE GENOME | | Carbamide derivative 21 | | |
7422 | VEGFA | CLINICALLY ACTIONABLE, GROWTH FACTOR, CELL SURFACE, DRUGGABLE GENOME | | FENOFIBRATE | FENOFIBRATE | 11356390 |
7422 | VEGFA | CLINICALLY ACTIONABLE, GROWTH FACTOR, CELL SURFACE, DRUGGABLE GENOME | | Quinoline and quinazoline derivative 4 | | |
7422 | VEGFA | CLINICALLY ACTIONABLE, GROWTH FACTOR, CELL SURFACE, DRUGGABLE GENOME | | Navicixizumab | NAVICIXIZUMAB | |
7422 | VEGFA | CLINICALLY ACTIONABLE, GROWTH FACTOR, CELL SURFACE, DRUGGABLE GENOME | inhibitor | CHEMBL1742982 | AFLIBERCEPT | |
7422 | VEGFA | CLINICALLY ACTIONABLE, GROWTH FACTOR, CELL SURFACE, DRUGGABLE GENOME | | PENTOSAN POLYSULFATE | | 17071199 |
7422 | VEGFA | CLINICALLY ACTIONABLE, GROWTH FACTOR, CELL SURFACE, DRUGGABLE GENOME | | Carbamide derivative 20 | | |